A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC) Meeting Abstract


Authors: Sugarman, R.; Botteman, M.; Rusibamayila, N.; Nguyen, H.; Lin, D.
Abstract Title: A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
Meeting Title: 2022 ASCO Gastrointestinal Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 4 Suppl.
Meeting Dates: 2022 Jan 20-22
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-02-01
Language: English
ACCESSION: WOS:000770995900265
DOI: 10.1200/JCO.2022.40.4_suppl.273
PROVIDER: wos
Notes: Meeting Abstract: 273 -- Meeting was conducted online as well as in person -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work